Merck claims a needed win for Keytruda with interim OS data in head and neck cancer
Merck has stocked up on data to support moving Keytruda up as a first-line therapy for head and neck squamous cell carcinoma.
An interim analysis of the Keynote-048 study suggested that the checkpoint inhibitor significantly improved overall survival — one of two primary endpoints — in patients whose tumors expressed PD-L1. The dual-primary endpoint of progression-free survival, however, has not been reached.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters